Actavis
Morris Corporate Center III
400 Interpace Parkway
Parippany
New Jersey
07054
United States
Tel: 1-862-261-7000
Website: http://www.actavis.com/
Email: actavis@actavis.com
About Actavis
Actavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company has global and U.S. headquarters in Parsippany, New Jersey, USA, and international headquarters in Zug, Switzerland.Actavis is the world’s third-largest generics prescription drug manufacturer, with more than 750 products marketed globally through operations in more than 60 countries. Actavis’ global branded pharmaceutical business develops and markets products principally in Urology and Women’s Health, and is committed to developing and marketing biosimilars products in Women’s Health, Oncology and other therapeutic categories. In addition, Actavis is the fourth-largest U.S. generic pharmaceutical product distributor through its Anda, Inc. business, and also develops and out-licenses generic pharmaceutical products outside of the U.S. through its Medis third-party business.
"Twice As" Video
"Our Winning Way" Video
413 articles about Actavis
-
The settlement is a huge development for the class action lawsuit against Takeda, which has been going on since 2016.
-
The CMA said some pharmaceutical firms charge the NHS with excessively high prices for hydrocortisone tablets and paid off potential competitors to stay out of the market.
-
Release of Federal Database Reveals 76 Billion Opioid Pills Were Sold in the U.S. From 2006-2012
7/17/2019
A federal judge ordered that information on sales of opioids up to the year 2013 could be released. -
The FDA issues Warning Letters to biopharma, medical device and food companies when they find that a manufacturer has significantly violated FDA regulations. As of March 4, the agency issued 45 Warning Letters this year.
-
Actavis Infringes Orexo's Long Term Zubsolv® U.S. Patent ´330
1/11/2019
Orexo AB announces that the United States District Court for the District of Delaware has issued a final, non-appealable judgement that Actavis's generic Zubsolv products infringe Orexo's U.S. patent No. 8,940,330
-
Many of these directors do not publicly disclose their affiliation with the pharma companies in their nonprofit biographies, report shows.
-
Orexo Wins Appeal Against Actavis on Zubsolv Patent in the US
9/10/2018
Orexo AB (publ.) today announces that the US Court of Appeals for the Federal Circuit found Orexo's long term Zubsolv patent US 8,940,330 to be valid, and reversed the invalidity decision previously rendered by the District Court of Delaware in November 2016.
-
Actinium Appoints Robert N. Daly, Ph.D. to Newly Created Role of Vice President, Head of Clinical Operations
9/6/2018
Industry veteran to lead and execute operations for pivotal Phase 3 SIERRA trial for Iomab-B.
-
Last week, Teva Pharmaceutical released what tried to be an optimistic second-quarter financial report, despite revenues that had decreased by 18 percent and softening sales of its biggest product, Copaxone.
-
Iterum Therapeutics filed with the U.S. Securities and Exchange Commission (SEC) to initiate an initial public offering (IPO). The company hopes to raise $92 million.
-
Hikma Pharmaceuticals generic version of Advair has hit a stumbling block with the FDA.
-
Pernix Announces Patent Litigation Settlement Agreement With Actavis Concerning Zohydro ER
1/29/2018
The litigation has been pending in the U.S. District Court for the District of Delaware and resulted from Actavis’s submission of an ANDA to the FDA seeking approval to market a generic version of Zohydro ER.
-
Neos Therapeutics Announces Settlement with Actavis on Adzenys XR-ODT Patent Litigation
10/18/2017
Under the agreement, Neos has granted Actavis the right to manufacture and market its generic version of Adzenys XR-ODT under the Actavis ANDA beginning on September 1, 2025, or earlier under certain circumstances.
-
VIVUS Announces Settlement With Actavis On Qsymia Patent Litigation
7/6/2017
-
Allergan Coughs Up $15 Million for Failing to Disclose Merger Talks With Actavis
1/18/2017
-
Teva Announces Completion Of Sale Of UK And Ireland Actavis Assets And Operations Following European Commission Approval
1/9/2017
-
Actavis UK Raised Drug Prices 12,000 Percent, Watchdog Finds
12/16/2016
-
Actavis to Slash 200 Workers as Part of Teva's Consolidation Efforts
11/29/2016
-
Orexo: Favorable Outcome From Zubsolv Patent Infringement Litigation Against Actavis
11/16/2016
-
Teva Announces Closing Of Public Offerings Of American Depositary Shares And Mandatory Convertible Preferred Shares In Connection With Pending Acquisition Of Actavis Generics
12/8/2015